Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Review

    Thymoquinone in the clinical treatment of cancer: Fact or fiction?

    Majed M. AbuKhader1 Corresponding author

    1. 1Department of Pharmacy, Oman Medical College, Muscat, SULTANATE OF OMAN.

    CORRESPONDENCE

    Majed M. AbuKhader

    Department of Pharmacy, Oman Medical College, Muscat, SULTANATE OF OMAN.

    majed.abukhader@omc.edu.om

    Received: 13-02-2013; Revised: 05-04-2013.

    Volume 7, Issue 14 · pp. 117–120 · PUBLISHED · DOI: 10.4103/0973-7847.120509

    View on Pharmacogn. Rev. original site ↗

    ABSTRACT

    Thymoquinone (TQ) is the bioactive phytochemical constituent of the seeds oil of Nigella sativa. In vitro and in vivo research has thoroughly investigated the anticancer effects of TQ against several cancer cell lines and animal models. As a result, a considerable amount of information has been generated from research thus providing a better understanding of the anti‑proliferating activity of this compound. Therefore, it is appropriate that TQ should move from testing on the bench to clinical experiments. The purpose of this review is to highlight the potential of TQ as an anticancer agent and the chances of this compound in the clinical treatment of cancer, with special attention on breast cancer treatment.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      AbuKhader, M. M. (). Thymoquinone in the clinical treatment of cancer: Fact or fiction?. Pharmacognosy Reviews, 7(14), 117–120. https://doi.org/10.4103/0973-7847.120509